|Bid||34.31 x 900|
|Ask||34.75 x 1100|
|Day's Range||34.15 - 35.60|
|52 Week Range||9.85 - 84.49|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
DermTech's innovative skin treatment is making it easier and cheaper to test for skin cancer, causing the business to grow. Fast.
Kevin Sun, Chief Financial Officer at Dermtech (NASDAQ:DMTK), made a large insider sell on September 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Sun sold 4,276 shares of Dermtech at a price of $36.19 per share. The total transaction amounted to $154,748. Sun still owns a total of 150,561 of Dermtech worth, $5,100,253. Dermtech shares are trading down 4.12% at $33.88 at the time of this writing on Monda
DermTech (NASDAQ: DMTK) stock skyrocketed earlier this year. In this Motley Fool Live video recorded on Sept. 1, Motley Fool contributors Keith Speights and Brian Orelli address a viewer's question about whether there's reason to be concerned about DermTech. Keith Speights: Very quickly, Brian, let's hit one question before we end our segment.